INTRODUCTION: In locations that lack nearby cyclotron facilities for radionuclide production, generator-based (68)Ga radiopharmaceuticals might have clinical utility for positron emission tomography (PET) studies of myocardial perfusion and other physiological processes. METHODS: The lipophilic and monocationic (67)Ga-labeled gallium chelates of five novel hexadentate bis(salicylaldimine) ligands the bis(salicylaldimine), bis(3-methoxysalicylaldimine), bis(4-methoxysalicylaldimine), bis(6-meth,oxysalicylaldimine), and bis(4,6-dimethoxysalicylaldimine) of N,N'-bis(3-aminopropyl)-N,N'-dimethylethylenediamine (BAPDMEN), were prepared. The structure of the unlabeled [Ga(4-MeOsal)(2)BAPDMEN](+)PF(6)(-) salt was determined by X-ray crystallography, and the biodistribution of each of the (67)Ga-labeled gallium chelates was determined in rats following intravenous administration and compared with the biodistribution of [(86)Rb]rubidium chloride. RESULTS: The [Ga(4-MeOsal)(2)BAPDMEN](+)PF(6)(-) complex exhibited the expected pseudo-octahedral N(4)O(2)(2-) coordination sphere about the Ga(3+) center with a trans disposition of the phenolate oxygen atoms. All five (67)Ga radiopharmaceuticals were found to afford the desired myocardial retention of the radiogallium. The [(67/68)Ga][Ga(3-MeOsal)(2)BAPDMEN](1+) radiopharmaceutical appears to have the best properties for myocardial imaging, exhibiting 2% of the injected dose in the heart 1 min and 2 h postinjection and very high heart/nontarget ratios (heart/blood ratios of 7.6+/-1.0 and 54+/-10 at 1 and 120 min, respectively; heart/liver ratios of 1.8+/-0.4 and 39+/-3 at 1 and 120 min, respectively). CONCLUSIONS: Most of these new agents, particularly [(67/68)Ga][Ga(3-MeOsal)(2)BAPDMEN](1+), would appear superior to previously reported bis(salicylaldimine) ligands of N,N'-bis(3-aminopropyl)ethylenediamine as candidates for PET imaging of the heart with (68)Ga.
INTRODUCTION: In locations that lack nearby cyclotron facilities for radionuclide production, generator-based (68)Ga radiopharmaceuticals might have clinical utility for positron emission tomography (PET) studies of myocardial perfusion and other physiological processes. METHODS: The lipophilic and monocationic (67)Ga-labeled gallium chelates of five novel hexadentate bis(salicylaldimine) ligands the bis(salicylaldimine), bis(3-methoxysalicylaldimine), bis(4-methoxysalicylaldimine), bis(6-meth,oxysalicylaldimine), and bis(4,6-dimethoxysalicylaldimine) of N,N'-bis(3-aminopropyl)-N,N'-dimethylethylenediamine (BAPDMEN), were prepared. The structure of the unlabeled [Ga(4-MeOsal)(2)BAPDMEN](+)PF(6)(-) salt was determined by X-ray crystallography, and the biodistribution of each of the (67)Ga-labeled gallium chelates was determined in rats following intravenous administration and compared with the biodistribution of [(86)Rb]rubidium chloride. RESULTS: The [Ga(4-MeOsal)(2)BAPDMEN](+)PF(6)(-) complex exhibited the expected pseudo-octahedral N(4)O(2)(2-) coordination sphere about the Ga(3+) center with a trans disposition of the phenolate oxygen atoms. All five (67)Ga radiopharmaceuticals were found to afford the desired myocardial retention of the radiogallium. The [(67/68)Ga][Ga(3-MeOsal)(2)BAPDMEN](1+) radiopharmaceutical appears to have the best properties for myocardial imaging, exhibiting 2% of the injected dose in the heart 1 min and 2 h postinjection and very high heart/nontarget ratios (heart/blood ratios of 7.6+/-1.0 and 54+/-10 at 1 and 120 min, respectively; heart/liver ratios of 1.8+/-0.4 and 39+/-3 at 1 and 120 min, respectively). CONCLUSIONS: Most of these new agents, particularly [(67/68)Ga][Ga(3-MeOsal)(2)BAPDMEN](1+), would appear superior to previously reported bis(salicylaldimine) ligands of N,N'-bis(3-aminopropyl)ethylenediamine as candidates for PET imaging of the heart with (68)Ga.
Authors: Marcus Henze; Jochen Schuhmacher; Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Helmut R Mäcke; Michael Eisenhut; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2004-01-17 Impact factor: 9.236
Authors: M Henze; J Schuhmacher; P Hipp; J Kowalski; D W Becker; J Doll; H R Mäcke; M Hofmann; J Debus; U Haberkorn Journal: J Nucl Med Date: 2001-07 Impact factor: 10.057
Authors: Michael E Merhige; William J Breen; Victoria Shelton; Teresa Houston; Brian J D'Arcy; Anthony F Perna Journal: J Nucl Med Date: 2007-07 Impact factor: 10.057
Authors: Antonia Dimitrakopoulou-Strauss; Peter Hohenberger; Uwe Haberkorn; Helmut R Mäcke; Michael Eisenhut; Ludwig G Strauss Journal: J Nucl Med Date: 2007-07-13 Impact factor: 10.057
Authors: V Sharma; A Beatty; S P Wey; J Dahlheimer; C M Pica; C L Crankshaw; L Bass; M A Green; M J Welch; D Piwnica-Worms Journal: Chem Biol Date: 2000-05
Authors: Karl Plössl; Rajesh Chandra; Wenchao Qu; Brian P Lieberman; Mei-Ping Kung; Rong Zhou; Bin Huang; Hank F Kung Journal: Nucl Med Biol Date: 2007-11-19 Impact factor: 2.408
Authors: Gary L Griffiths; Chien-Hsing Chang; William J McBride; Edmund A Rossi; Agatha Sheerin; German R Tejada; Habibe Karacay; Robert M Sharkey; Ivan D Horak; Hans J Hansen; David M Goldenberg Journal: J Nucl Med Date: 2004-01 Impact factor: 10.057
Authors: Jae Min Jeong; Mee Kyung Hong; Young Soo Chang; Yun-Sang Lee; Young Joo Kim; Gi Jeong Cheon; Dong Soo Lee; June-Key Chung; Myung Chul Lee Journal: J Nucl Med Date: 2008-04-15 Impact factor: 10.057
Authors: Vijay Sharma; Jothilingam Sivapackiam; Scott E Harpstrite; Julie L Prior; Hannah Gu; Nigam P Rath; David Piwnica-Worms Journal: PLoS One Date: 2014-10-29 Impact factor: 3.240